
Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations

